Treating Opioid Use Disorder and Managing Chronic Pain in Today's Epidemic of Overdose Deaths
This workshop is designed for clinicians prescribing medication for the treatment of addiction and pain management. It will build skills using buprenorphine in the emergency department, hospital and ambulatory settings and managing challenging inductions such as from fentanyl. An updated comparison on the buprenorphine formulations and clinical use will be provided. We will help clinicians navigate the current climate of the overdose epidemic and the changing regulatory and Drug Enforcement Agency standards of care which mandate requirements for practice, documentation and record keeping. Topics include long-acting depot buprenorphine, transdermal and sublingual buprenorphine for pain, “low” and “high” dose inductions on to buprenorphine.
This workshop was recorded at the 2022 State of the Art conference.
PRICE/PURCHASE -- $125 (CSAM/ASAM MEMBERS); $250 (NON-MEMBERS)
You must sign in or register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button.
To purchase, click on the course (you do not need to select each lecture). After you have selected it, scroll to the bottom of the page and click "Add to Cart."
You will be able to work through the lectures in any order by clicking on the lecture in the table below. You may print out a CME certificate or transcript of your cumulative credits at any time.
This activity is designed for physicians treating patients with opioid use disorder or patients with chronic pain.
- Name two common interventions in OUD care that are not evidence based and provide barriers to treatment.
- Describe three characteristics of a low barrier practice.
- Explain the data supporting low barrier practices.
Telemedicine Practice, Standard of Care and OUD Treatment | David Kan, MD, DFASAM
Buprenorphine Flavors & Formulations...Past, Present and Future | Matt Torrington, MD, ABPM, ABFM, DFASAM
Low Dose Induction in the Inpatient and Outpatient Settings | Julio Meza, MD
Low Barrier Buprenorphine | Hannah Snyder, MD, presented by David Kan, MD, DFASAM
David Kan, MD
Dr. Kan graduated from Northwestern University Medical School. He finished his General Psychiatry Residency and Forensic Psychiatry Fellowship at the University of California, San Francisco (UCSF). He is Board-certified by the American Board of Psychiatry and Neurology in General and Forensic Psychiatry and he is Board-Certified by the American Board of Addiction Medicine in Addiction Medicine.
No relevant financial relationships to disclose.
Julio Meza, MD
Dr. Julio Meza is an Addiction and Family Medicine Physician at the David Geffen School of Medicine at UCLA and a Psychiatry in Primary Care Certified Physician at UC Irvine. He graduated Cum Laude from Universidad Evangelica de El Salvador. After graduating from medical school, he was accepted into a surgical residency and completed an internship at the Hospital Militar Central in El Salvador. He left El Salvador to pursue his dream of becoming a U.S. licensed family physician. While in Los Angeles, Dr. Meza worked as a medical assistant instructor and program director, training students to work in the areas of San Fernando, North Hollywood and Los Angeles then joined UCLA and completed his residency in Family Medicine and also Fellowship in Addiction Medicine. Dr. Meza enjoys working with patients from all backgrounds and provides non judgmental compassionate care.
Matthew A. Torrington, MD, DFASAM
Dr. Torrington is a board certified in Family Medicine and Addiction Medicine. He is a distinguished fellow of the American Society of Addiction Medicine, the chair of the Committee on Treatment of Opioid Dependence of the California Society of Addiction Medicine, and is a certified Medical Review Officer. For over twenty years, Dr Torrington has been involved in the clinical use, clinical research, and education of physicians regarding various formulations of buprenorphine.
Hannah Snyder, MD
Hannah Snyder is an Assistant Professor of Family and Community Medicine at UCSF. She graduated from medical school at the University of Chicago and residency in Family and Community Medicine at UCSF before completing the Addiction Medicine Fellowship at UCSF. She is a founder and principal investigator of the CA Bridge program, which supports over 160 California hospitals in providing care for people who use drugs. Hannah practices primary care and addiction medicine at Zuckerberg San Francisco General Hospital.
The California Society of Addiction Medicine (CSAM) is accredited by the California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.
CSAM designates this virtual educational activity for a maximum of 2.5 AMA PRA Category 1 Credits™, Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
In accordance with the ACCME Standards for Integrity and Independence, CSAM adheres to guidelines and processes to identify and mitigate relevant financial relationships for all individuals in a position to control the content of this activity. Unless otherwise noted, faculty did not have any relevant financial relationships with ineligible companies, as defined by ACCME, within the past 24 months. All relevant financial relationships have been mitigated.
- 2.50 AMA Category 1
- 2.50 Attendance